权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Purinergic Modulation of Dermal Fibrosis

真皮纤维化的嘌呤能调节

基本信息

批准号：
8136837
负责人：
EDWIN SL CHAN
金额：
$ 8.11万
依托单位：
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-01 至 2012-08-31
项目状态：
已结题

项目摘要

DESCRIPTION (provided by applicant): Dermal fibrosis is a hallmark of systemic sclerosis. We have previously demonstrated that stimulation of adenosine A2A receptor promotes collagen production in vitro while blockade of the adenosine A2A receptor attenuates development of dermal fibrosis in vivo in a bleomycin-induced murine model of scleroderma. These findings parallel our observations on models of hepatic fibrosis where adenosine A2A receptor antagonists retard chemically-induced murine cirrhosis. We have recently shown that levels of the fibrogenic cytokine, IL-13 are elevated in the skin in a murine model of high tissue adenosine (adenosine deaminase deficiency). Furthermore, an A2A receptor antagonist reverses the IL-13 increase and decreases message for IL-13 receptor 1. To better understand the mechanisms by which adenosine A2A receptor antagonism protects against dermal fibrogenesis in scleroderma, we will study: Specific Aim 1 The effect of adenosine on IL-13 responsiveness in dermal fibroblasts Specific Aim 2 The effect of adenosine and IL-13 on Fli1 function Specific Aim 3 The effect of adenosine on CCN2. Ultimately, we hope that these studies will allow us to consider the use of small molecules such as adenosine receptor antagonists in the therapy of dermal fibrosis in scleroderma. PUBLIC HEALTH RELEVANCE: NARRATIVE Uncontrolled and excessive fibrous tissue formation may result in diffuse skin and organ fibrosis such as that seen in scleroderma. The studies proposed herein are designed to further confirm the role of adenosine and its receptors in promoting fibrosis in the skin as well as the mechanisms by which adenosine receptors stimulate tissue matrix production. A better understanding of the role of adenosine and its receptors in dermal fibrosis could facilitate the development of new agents that prevent or ameliorate the skin fibrosis that characterizes scleroderma, for which no effective treatment exists at present.

描述（由申请人提供）：皮肤纤维化是系统性硬化症的标志。我们以前已经证明，腺苷A2 A受体的刺激，促进胶原蛋白的生产在体外，而腺苷A2 A受体的阻断，减弱发展的真皮纤维化在体内的博莱霉素诱导的硬皮病小鼠模型。这些发现与我们在肝纤维化模型上的观察结果一致，其中腺苷A2 A受体拮抗剂延缓化学诱导的小鼠肝硬化。我们最近发现，在高组织腺苷（腺苷脱氨酶缺乏症）的小鼠模型中，皮肤中的纤维化细胞因子IL-13水平升高。此外，A2 A受体拮抗剂逆转IL-13增加并减少IL-13受体1的信息。为了更好地了解腺苷A2 A受体拮抗剂保护硬皮病皮肤纤维化的机制，我们将研究：特异性目的1腺苷对皮肤成纤维细胞中IL-13反应性的影响特异性目的2腺苷和IL-13对Fli 1功能的影响特异性目的3腺苷对CCN的影响2。最终，我们希望这些研究将使我们能够考虑使用小分子，如腺苷受体拮抗剂治疗硬皮病的真皮纤维化。公共卫生相关性：不受控制的和过度的纤维组织形成可导致弥漫性皮肤和器官纤维化，如硬皮病所见。本文提出的研究旨在进一步证实腺苷及其受体在促进皮肤纤维化中的作用以及腺苷受体刺激组织基质产生的机制。更好地了解腺苷及其受体在皮肤纤维化中的作用，可以促进开发新的药物，预防或改善硬皮病的皮肤纤维化，目前还没有有效的治疗方法。